Belinostat Patent Expiration
Belinostat is Used for treating relapsed or refractory peripheral T-cell lymphoma (PTCL). It was first introduced by Acrotech Biopharma Inc
Belinostat Patents
Given below is the list of patents protecting Belinostat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Beleodaq | US8835501 | Pharmaceutical formulations of HDAC inhibitors | Oct 27, 2027 | Acrotech Biopharma |
| Beleodaq | US6888027 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | Aug 10, 2026 | Acrotech Biopharma |
Belinostat's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List